Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Operating Leases: 2020-2025

Historic Operating Leases for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $13.7 million.

  • Apellis Pharmaceuticals' Operating Leases rose 19.88% to $13.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year increase of 19.88%. This contributed to the annual value of $10.2 million for FY2024, which is 10.94% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Operating Leases stood at $13.7 million for Q3 2025, which was up 64.56% from $8.3 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Operating Leases high stood at $19.9 million for Q1 2021, and its period low was $8.3 million during Q2 2025.
  • For the 3-year period, Apellis Pharmaceuticals' Operating Leases averaged around $11.0 million, with its median value being $11.1 million (2024).
  • Per our database at Business Quant, Apellis Pharmaceuticals' Operating Leases skyrocketed by 78.16% in 2021 and then fell by 28.83% in 2023.
  • Quarterly analysis of 5 years shows Apellis Pharmaceuticals' Operating Leases stood at $17.1 million in 2021, then fell by 15.98% to $14.4 million in 2022, then dropped by 20.19% to $11.5 million in 2023, then decreased by 10.94% to $10.2 million in 2024, then rose by 19.88% to $13.7 million in 2025.
  • Its last three reported values are $13.7 million in Q3 2025, $8.3 million for Q2 2025, and $9.2 million during Q1 2025.